BCDA/BCDAW: Press Release Furnished Announcing Quarter Ended June 30, 2025

Rhea-AI Filing Summary

BioCardia, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is being furnished rather than "filed" with the SEC, so it is not subject to the liabilities of a filed report and is not incorporated by reference into other filings unless explicitly stated.

The 8-K confirms the company’s securities trade on the Nasdaq Capital Market under the tickers BCDA (common stock) and BCDAW (warrants). No financial figures or operational details are included in the 8-K text itself; those details are contained in the furnished press release (Exhibit 99.1).

Insights

Financial Analyst

TL;DR: Routine results release furnished as Exhibit 99.1; no financial data is included in the 8-K itself.

The filing is procedural: it furnishes a press release containing quarterly results for the period ended June 30, 2025. Because the 8-K explicitly states the press release is "furnished" and not "filed," liability protections differ and the content is not automatically incorporated by reference into other filings. Investors must review Exhibit 99.1 for the actual metrics and any commentary on performance, guidance, or material developments. The 8-K does confirm listing symbols on Nasdaq, but provides no earnings, revenue, or cash position data within the filing text.

Corporate Governance Expert

TL;DR: Standard disclosure practice to furnish earnings press release; governance implications are limited absent additional detail.

This 8-K follows common practice of furnishing an earnings press release as Exhibit 99.1 and clarifies its furnished (not filed) status, which affects incorporation and liability. There are no governance actions, executive changes, or material transactions disclosed in the filing text. Any governance-relevant statements would need to be examined within the attached press release.

false 0000925741 0000925741 2025-08-11 2025-08-11 0000925741 bcda:CommonStockParValue0001CustomMember 2025-08-11 2025-08-11 0000925741 bcda:WarrantToPurchaseCommonStockCustomMember 2025-08-11 2025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

BIOCARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38999		23-2753988
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

320 Soquel Way
Sunnyvale, California 94085

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market
Warrant to Purchase Common Stock	BCDAW	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2025, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02, including the Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		BioCardia, Inc. press release dated August 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.

/s/ Peter Altman, Ph.D.

Peter Altman, Ph.D.

President and Chief Executive Officer

Date: August 11, 2025

FAQ

What did BioCardia (BCDAW) disclose in this 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1.

Is the press release in this 8-K "filed" with the SEC?

No. The 8-K states the press release is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Which securities of BioCardia are listed and what are the tickers?

Common stock trades on the Nasdaq Capital Market under BCDA and warrants trade under BCDAW.

Does the 8-K include financial figures for the quarter?

No. The 8-K text does not include financial numbers; those details are contained in the furnished press release (Exhibit 99.1).

Which exhibit contains the press release?

Exhibit 99.1 contains the BioCardia press release announcing quarterly results.